



## **Effectiveness of Continuous Diffusion of Oxygen Adjunct Therapy to Improve Success Rate of Lower Extremity Surgically Closed Wound**


Alejandro Zulbaran, MD, Naima Rodriquez, MA, Sogol Golafshan, BS, Brian Lepow, DPM, Jeffrey Ross, DPM, MD, Bijan Najafi, PhD

Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery Baylor College of Medicine, Houston, TX, USA



TO ASSESS THE USEFULNESS OF CONTINUOUS OXYGEN DIFFUSION TO BOOST HEALING PROCESS OF SURGICALLY CLOSED WOUNDS

INTRODUCTION	MATERIALS & METHODS
<ul> <li>Significance &amp; Impact: Surgical wound complications such as tissue necrosis, infection, and dehiscence are highly prevalent in diabetic patients undergoing podiatric open interventions<sup>1,2</sup>.</li> <li>Tissue necrosis delay healing and prolong the inflammatory response, impeding re-epithelialization<sup>3</sup>.</li> <li>Gaps: Currently there is no known therapy to reduce likelihood of tissue necrosis.</li> <li>Premise: Level of transcutaneous oxygen could be a determinant factor in formation of tissue necrosis<sup>4</sup>. Thus a new method to improve surgical wound oxygenation may reduce likelihood of tissue necrosis.</li> </ul>	<ul> <li>Study design: RCT (N=19) of patients undergoing foot open surgery</li> <li>Control Group (n = 7): standard of care</li> <li>Intervention Group (n = 11): standard of care plus TransCu O2® device</li> <li>Duration: 4 weeks</li> <li>Criteria</li> <li>Inclusion: 18-85 yrs diabetic patients, presence of a surgically closed wound due to minor lower extremity amputation.</li> <li>Exclusion: Charcot arthropathy, major amputation, osteomyelitis, extreme gangrene, or excessive lymphedema</li> <li>Outcomes</li> </ul>
<ul> <li>Our specific aim: We proposed a proof of concept randomized control trial to examine effectiveness of a new dressing (TransCu O2 ®, O2 Concept, TX, Fig. 1) that supports continuous oxygen delivery (CDO) to the surgical site. We hypothesize that CDO is effective to accelerate wound healing process, reduce likelihood, of tissue percess, and improve vascular factors in people with</li> </ul>	<ul> <li>Primary: Necrosis, dehiscence, change in incision size.</li> <li>Secondary: Tissue oxygen level quantified by SatO2 (Fig. 2), % wound reduction at 4 wks.</li> <li>Statistical Analysis: General linear model</li> </ul>



- 75% in IG v. 29% in CG (p=0.059)
- which led to revision of protocol
- After revision, no adverse events

# **DISCUSSION & CONCLUSION**

- is the first study reporting **D** This potential effectiveness of CDO in improving surgically closed wound outcomes for diabetic patients.
- □ The results support proof of concept feasibility, acceptability and noticeable trend in favor of CDO to accelerate healing in surgically closed wounds and reduce like hood of AEs.

### REFERENCES

- Chandan K. Sen, et al. Wound Repair Regan. 2009; 17(1): 1-18. 1.
- Brian Wernick, et al. StatPearls Publishing; 2020. 2.
- Zegers, M. Patient Sat Surg. 2011;5:13. 3.
- Ryan D, et al. StatPearls Publishing; 2020. Δ.

#### ACKNOWLEDGEMENT

- This study was supported in part by a grant from EO2 Concepts. Sponsors did not contribute in participant recruitment nor in data analysis or interpretation of results.
- ClinicalTrials.gov The study was registered in identifier: NCT03960463.

